BRAF and neoplasm: Activating mutations of KRAS codon 12 were detected in four patients, and oncogenic mutations of NRAS (G13V) and BRAF (V600E) were each identified in one additional tumor, contributing to a prevalence of 54.4% for activating mutations of RAS pathway.